http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BioLineRx (BLRX) Reports Successful Engraftment Data from Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
-
BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
-
BioLineRx to Report Annual 2018 Results on March 28, 2019
-
BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
-
BioLineRx (BLRX) Announces Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
-
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
-
BioLineRx to Present at the 2019 Biotech Showcase
-
BioLineRx (BLRX) Commences Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
-
BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
-
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
-
BioLineRx (BLRX) Receives FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
-
BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
-
BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update
-
BioLineRx to Report Third Quarter 2018 Results on November 8, 2018
-
BioLineRx Discloses Additional Data from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
-
BioLineRx (BLRX) Reports Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
-
BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
-
BioLineRx (BLRX) Reports Agreement with Biokine Therapeutics to Boost Stake in BL-8040 to 80% (from 60%)
-
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
-
BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York
-
BioLineRx Reports Second Quarter 2018 Financial Results
-
BioLineRx (BLRX) Reports Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
-
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
-
BioLineRx to Report Second Quarter 2018 Results on August 13, 2018
-
BioLineRx (BLRX) Commences Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
-
BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
-
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
-
BioLineRx (BLRX) Highlights New Overall Survival Data from Phase 2a Study for BL-8040 in r/r AML Patients
-
BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients
-
BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference
-
BioLineRx Reports First Quarter 2018 Financial Results
-
BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients
-
BioLineRx (BLRX) Announces Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization
-
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
-
BioLineRx to Report First Quarter 2018 Results on May 22, 2018
-
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
-
BioLineRx (BLRX) Announces Notice of Allowance From USPTO for Patent Covering AGI-134
-
BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
-
BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference
-
BioLineRx Reports Year End 2017 Financial Results
-
BioLineRx to Report Annual 2017 Results on March 6, 2018
-
BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13
-
BioLineRx (BLRX) Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival
-
BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
-
BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies
-
BioLineRx (BLRX) Reports Partial Monotherapy Results from Phase 2A COMBAT Study in Pancreatic Cancer
-
BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer
-
UPDATE: BioLineRx Ltd. (BLRX) Reports Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
-
BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
-
BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
